Home / Pharmacology / Enzyme-Linked Receptors / Receptor Tyrosine Kinases (RTKs) / EGFR

EGFR

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family. Four members of the ErbB family have been identified; EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4). EGFR signaling drives many cellular responses.

Products
Background
Literature (4)
Gene Data

Inhibitors
Cat. No. Product Name / Activity
5318 AEE 788
Potent EGFR and VEGFR inhibitor
6812 Afatinib dimaleate
Potent dual specificity EGFR/HER2 inhibitor; active in vivo
1276 AG 1478 hydrochloride
Highly potent EGFR-kinase inhibitor
0493 AG 18
EGFR/PDGFR-kinase inhibitor
0414 AG 490
EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor
0619 AG 494
Potent EGFR-kinase inhibitor
0618 AG 555
Potent EGFR-kinase inhibitor
1555 AG 825
Selective ErbB2 inhibitor
2617 AG 879
ErbB2 inhibitor
0497 AG 99
EGFR-kinase inhibitor
4397 AV 412
Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinases
2417 BIBU 1361 dihydrochloride
Selective inhibitor of EGFR-kinase
2416 BIBX 1382 dihydrochloride
Highly selective EGFR-kinase inhibitor
5022 BMS 599626 dihydrochloride
Potent, selective EGFR and ErbB2 inhibitor
5916 Canertinib dihydrochloride
Potent EGFR kinase inhibitor
3360 CGP 52411
EGFR inhibitor. Also inhibits Aβ42 fibril formation
5973 CP 724714
Potent and selective ErbB2 inhibitor
6231 Dacomitinib
Potent irreversible pan ErbB inhibitor
4502 DIM
Inhibits EGFR activation; also induces apoptosis
1110 Genistein
EGFR kinase inhibitor. Also estrogen and PPARγ ligand
2239 GW 583340 dihydrochloride
Potent dual EGFR/ErbB2 inhibitor; orally active
3580 HKI 357
Dual irreversible inhibitor of ErbB2 and EGFR
3000 Iressa
Orally active, selective EGFR inhibitor
6962 JBJ-03-142-02
Highly potent EGFR and ErbB2 inhibitor; inhibts wild type and mutated receptors
3352 JNJ 28871063 hydrochloride
Potent ErbB receptor family inhibitor
6811 Lapatinib
Potent and selective dual ErbB2 (HER-2) and EGFR inhibitor
1331 Lavendustin A
EGFR, p60c-src inhibitor
0577 Methyl 2,5-dihydroxycinnamate
EGFR-kinase inhibitor
1037 PD 153035 hydrochloride
EGFR-kinase inhibitor
2615 PD 158780
Potent ErbB receptor family inhibitor
6349 Pelitinib
Potent and irreversible EGFR inhibitor; orally bioavailable
5939 PF 6274484
High affinity and potent covalent EGFR kinase inhibitor
4941 PKI 166 hydrochloride
Potent EGFR-kinase inhibitor
2794 PP 3
EGFR-kinase inhibitor. Also Src kinase negative control
3599 TAK 165
Potent and selective ErbB2 inhibitor
0579 Tyrphostin B44, (+) enantiomer
EGFR-kinase inhibitor
3115 WHI-P 154
Potent EGFR inhibitor. Also inhibits JAK3

Degraders
Cat. No. Product Name / Activity
7258 Gefitinib-based PROTAC® 3
Potent EGFR Degrader
7261 SJF 1521
Selective EGFR Degrader
7262 SJF 1528
Potent EGFR Degrader; also degrades HER2

Other
Cat. No. Product Name / Activity
6556 Anti-human EGFR aptamer, Janelia Fluor® 646 conjugate
High affinity anti-human EGFR aptamer conjugated to Janelia Fluor® 646
6557 Anti-human ErbB2 aptamer, Janelia Fluor® 646 conjugate
Anti-human ErbB2 aptamer, Janelia Fluor® 646 conjugate

Related Targets

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family. Four members of the ErbB family have been identified: EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4).

EGFR signaling is initiated by ligand binding to the extracellular ligand binding domain. This initiates receptor homo-/heterodimerization and autophosphorylation by the intracellular kinase domain, resulting in receptor activation. Following activation, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, decreased apoptosis and increased cell proliferation.

External sources of pharmacological information for EGFR :

Literature for EGFR

Tocris offers the following scientific literature for EGFR to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Kinases

Kinases Product Listing

A collection of over 400 products for kinase research, the listing includes inhibitors of:

  • Receptor Tyrosine Kinases
  • Protein Kinases A, C, D and G
  • PI-3 Kinase, Akt and mTOR
  • MAPK Signaling
  • Receptor Serine/Threonine Kinases
Angiogenesis in Cancer

Angiogenesis in Cancer Poster

Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.

EGF Receptor Gene Data

Gene Species Gene Symbol Gene Accession No. Protein Accession No.
EGFR Human EGFR NM_005228 P00533
Mouse Egfr NM_207655 Q01279
Rat Egfr NM_031507 Q62954
ErbB2 Human ERBB2 NM_001005862 P04626
Mouse Erbb2 NM_001003817 P70424
Rat Erbb2 NM_017003 P06494
ErbB3 Human ERBB3 NM_001005915 P21860
Mouse Erbb3 NM_010153 Q61526
Rat Erbb3 NM_017218 Q62799
ErbB4 Human ERBB4 NM_001042599 Q15303
Mouse Erbb4 NM_010154 Q61527
Rat Erbb4 NM_021687 Q62956